Marketed Products

Featured Marketed Products

Kyprolis

Kyprolis® (carfilzomib) for Injection is a Proteosome inhibitor indicated for the treatment of patients with multiple myeloma.

At a Glance

Licensee Indication Royalty
Amgen Multiple Myeloma 1.5-3.0%

EVOMELA

Captisol-enabled formulation of Melphalan which is used for stem cell transplant conditioning in multiple myeloma. Captisol improves product stability and enables the removal of propylene glycol, which is associated with renal and cardiac toxicities.

At a Glance

Partner Indication Royalty
Spectrum Oncology 20%

Baxdela

Novel antibiotic indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.

At a Glance

Partner Indication Royalty
Melinta Therapeutics Infectious Disease 2.5%

Additional Marketed Products

IV Voriconazole

Captisol-enabled IV formulation of voriconazole

At a Glance

Partner Indication Royalty
Alvogen Infectious Disease Material sales only

Duavee

DUAVEE (conjugated estrogens/bazedoxifene) is a progesterone-free treatment for moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause and aids in the prevention of postmenopausal osteoporosis.

At a Glance

Partner Indication Royalty
Pfizer Menopause 0.5-2.5%

Viviant/Conbriza

Viviant/Conbriza™ (bazedoxifene) is a synthetic drug that was specifically designed to reduce the risk of osteoporotic fractures, while at the same time protecting breast and uterine tissue.

At a Glance

Partner Indication Royalty
Pfizer Osteoporosis 0.5-2.5%

Nexterone

NEXTERONE (amiodarone HCl) Premixed Injection is indicated for initiation of treatment and prophylaxis for frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to the therapy.

At a Glance

Partner Indication Royalty
Baxter Arrhythmia Undisclosed

Noxafil-IV

Captisol-enabled IV formulation of Noxafil

At a Glance

Partner Indication Royalty
Merck Infectious Disease Material sales only

ZULRESSOâ„¢

ZULRESSO, the first medicine specifically approved by the U.S. Food and Drug Administration for the treatment of postpartum depression, is an allosteric modulator of both synaptic and extrasynaptic GABAA receptors. Allosteric modulation of neurotransmitter receptor activity results in varying degrees of desired activity rather than complete activation or inhibition of the receptor. ZULRESSO is approved by the FDA for the treatment of PPD in adults, pending DEA scheduling. ZULRESSO has been granted PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA). We have the potential to receive milestone payments, royalties and revenue from Captisol material sales for Captisol-enabled programs. SAGE is responsible for all development costs related to the program.

At a Glance

Partner Indication Royalty
Sage Therapeutics CNS 3%